FDA Approves Endo’s Ephedrine Sulfate Injection

Endo’s subsidiary Par Pharmaceutical received final approval from the FDA for its NDA for ephedrine sulfate injection.

The drug is administered intravenously to address hypotension in surgical settings.

Ephedrine sulfate for injection is packaged in cartons of single use vials. Par expects to begin shipping the product in February 2017.